New study tracks safety of psoriasis drug in pregnancy
NCT ID NCT03992729
First seen Feb 01, 2026 · Last updated May 12, 2026 · Updated 14 times
Summary
This study follows pregnant women who take tildrakizumab for approved conditions and compares them to pregnant women with the same condition who do not take the drug. Researchers track pregnancy outcomes and infant health up to one year after birth. The goal is to understand if tildrakizumab poses any risks during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREGNANCY RELATED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Christina Chambers
RECRUITINGSan Diego, California, 92093, United States
Conditions
Explore the condition pages connected to this study.